Skip to main content

AHUS - Atypical Hemolytic Uremic Syndrome

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

NovelMed Therapeutics
NovelMed TherapeuticsOH - Cleveland
1 program
NM8074PHASE_21 trial
Active Trials
NCT05684159Not Yet Recruiting12Est. Feb 2031

Trial Timeline

Clinical trial activity over time

2026
2027
2028
2029
2030
2031
NovelMed TherapeuticsNM8074

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

Start: Nov 2027Est. completion: Feb 203112 patients
Phase 2Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.